Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1714079

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gabapentin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Medicines and Healthcare products Regulatory Agency on (a) its advice on prescribing and (b) the side effects of gabapentin.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	23890
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>Gabapentin is authorised for the treatment of some forms of epilepsy, as well as peripheral neuropathic pain. The product information for gabapentin, approved by the Medicines and Healthcare products Regulatory Agency (MHRA), provides information to support the prescribing of the medication including recommendations for dose, duration of use, as well as gradual reduction when stopping. The product information includes warnings about possible side effects.</p><p>The MHRA continuously monitors the safety of gabapentin and ensures the product information reflects what is known about the medicine and its side effects.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 01/05/2024 09:02:05 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4471 label Biography information for Rachael Maskell

1714080

registered interest
date	26/04/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gabapentin
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if she will take steps to ensure that people experiencing acute or chronic side effects from taking gabapentin do not have to wait for a (a) referral and (b) assessment by mental health services.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	23891
answer	answer is ministerial correction date of answer 01/05/2024 answer text <p>While we have no specific plans to do so, we are committed to expanding and transforming mental health services in England through the NHS Long Term Plan, so that more people, including those experiencing side effects from taking gabapentin, can get the mental health help and support that they need.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 01/05/2024 15:56:56 answering member 4492 label Biography information for Maria Caulfield
tabling member	4471 label Biography information for Rachael Maskell